The 130-year old healthcare conglomerate sells everything from baby shampoo to surgical staples and cancer drugs (it also divested itself of Splenda, the artificial sweetener.) That diversification helped buoy giant J&J in 2015; the company’s strong pharmaceutical sales made up for the less impressive performances of its consumer and medical device divisions. The company’s revenues grew 2.6% in the US, but slid 5.7% worldwide in 2015, largely due to currency fluctuations and the sharp decline in sales of its Hepatitis C drug, Olysio.
News about Johnson & Johnson
Its main drug couldn't beat a placebo.
Its planned $66 billion Monsanto buy had stirred criticism it might neglect its pharmaceuticals.
More than at Pfizer, Merck, and Amgen
Both candidates have promised to release more info. Here's what we need to know.
Videos about Johnson & Johnson
According to this Johnson & Johnson exec